Biomatics Capital

Biomatics Capital is a Seattle-based venture capital firm specializing in early-stage investments at the intersection of healthcare and technology. The firm focuses on sectors such as genomics and digital health, aiming to drive the evolution of healthcare through data-driven innovations. Biomatics Capital manages a $200 million fund, co-founded by Dr. Boris Nikolic and Julie Sunderland, who have been investing together since 2010. Their deep technical knowledge and extensive network enable them to identify and support emerging technology, healthcare, and life science ventures. The firm's investment strategy encompasses a wide range of stages, including Seed, Early Stage, Series A, Series B, Growth, Late Stage, and Pre-IPO, with investment sizes typically ranging from $1 million to $50 million. Biomatics Capital's portfolio includes companies like eGenesis, Verve Therapeutics, Omniome, and Twist Bioscience, reflecting its commitment to advancing healthcare through innovative technologies. The firm's approach combines scientific expertise with business acumen, providing portfolio companies with strategic guidance and access to a network of leading academics, pharmaceutical executives, and venture capital firms. This collaborative approach aims to create long-term successful companies with impactful strategies in the healthcare sector. Biomatics Capital's focus on transformative innovations positions it as a key player in shaping the future of healthcare and medicine, leveraging the convergence of genomics and digital data to develop superior therapeutics, diagnostics, and delivery models. By investing in cutting-edge science, the firm seeks to lower costs and improve patient outcomes, contributing to a value-based healthcare system. Through its strategic investments and partnerships, Biomatics Capital continues to play a pivotal role in advancing healthcare solutions that address critical medical needs and enhance the quality of care.